Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
11/2013
11/20/2013CN102256625B Mono- and di-peg il-10 production
11/20/2013CN102100915B Chlorambucil multi-targeting medicine carrying system and preparation method and application thereof
11/20/2013CN102048734B Pharmaceutical composition
11/20/2013CN101797382B Anti-human progastrin polypeptide immune composition
11/20/2013CN101606908B Decoquinate soluble powder and preparation method thereof
11/20/2013CN101500991B Lipoic acid derivatives
11/20/2013CN101460151B Pharmaceutical formulations: salts of 8-[{1-(3,5-bis (trifluoromethy1)pheny1)-e thoxy}-methy1]-8-pheny1-1,7-diaza-spiro[4.5] decan-2-one and treatment methods using the same
11/19/2013US8586681 Multi-arm block copolymers as drug delivery vehicles
11/19/2013US8586671 Biocompatible phase invertible proteinaceous compositions and methods for making and using the same
11/19/2013US8586638 Parakeratosis inhibitor and skin preparation for external use
11/19/2013US8586637 Stable and compatible polymer blends
11/19/2013US8586555 Immunomodulatory compositions, formulations, and methods for use thereof
11/19/2013US8586529 Composition for preventing and improving metabolic syndrome
11/19/2013US8586088 Tamper-resistant oral opioid agonist formulations
11/19/2013US8586076 Compositions comprising dietary fat complexer and methods for their use
11/19/2013US8586066 Topical antifungal composition
11/19/2013US8586049 Antibody-drug conjugates
11/19/2013US8586020 Poly(organophosphazene) composition for biomaterials
11/19/2013US8586007 Co-polymer stabilizers for hydrofluoroalkane dispersions
11/19/2013CA2786330C A pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one with improved storage and solubility properties
11/19/2013CA2771188C Passive solid tumor-targeted pectin-doxorubicin prodrug and preparation method thereof
11/19/2013CA2722050C Polymerized micelles
11/19/2013CA2645110C Pharmaceutical composition for external use
11/19/2013CA2640997C Doxorubicin formulations for anti-cancer use
11/19/2013CA2634073C Compositions comprising ingenol-3-angelate
11/19/2013CA2613976C New pharmaceutical compositions containing hyaluronic acid and collagenase for the topical treatment of wounds, burns and ulcers
11/19/2013CA2609572C A method for preparing a stable immunogenic product comprising antigenic heterocomplexes of tnf.alpha. and a carrier protein
11/19/2013CA2603853C Polymeric micelles for drug delivery
11/19/2013CA2572380C Gemcitabine derivatives nanoparticles
11/19/2013CA2447139C Specific binding proteins and uses thereof
11/19/2013CA2425842C Use of il-1 inhibitors and tnf antagonists, partially in combination with recombinant erythropoietins, for the treatment of anemia
11/19/2013CA2305620C Method for the covalent attachment of polysaccharides to protein molecules
11/15/2013CA2815477A1 Pharmaceutical composition
11/14/2013WO2013170085A1 A positron emission tomography probe to monitor selected sugar metabolism in vivo
11/14/2013WO2013169989A1 Method and compounds for inhibiting the mcm complex and their application in cancer treatment
11/14/2013WO2013169925A1 Novel formulations of nitrofurans including nifurtimox with enhanced activity with lower toxicity
11/14/2013WO2013169897A1 Cylodextrin complexation methods for formulating peptide proteasome inhibitors
11/14/2013WO2013169724A1 Implantable medical devices comprising a water - insoluble therapeutic agent and xylitol, iodine or edta
11/14/2013WO2013169614A1 Method of treating amd in patients refractory to anti-vegf therapy
11/14/2013WO2013169547A1 Treatment for comorbid diabetes with chronic kidney disease
11/14/2013WO2013169458A1 Pharmaceutical compositions and methods for treating, controlling, ameliorating, or reversing conditions of dry eye
11/14/2013WO2013169337A1 Polymer conjugates with a linker
11/14/2013WO2013168858A1 Capsule composition containing inorganic nanoparticles for uv protection using of hydrogel-forming polymers, and method for preparing same
11/14/2013WO2013168437A1 Organic compound nanopowder, production method therefor, and suspension
11/14/2013WO2013168402A1 Dextran-containing mammalian cell suspension for prevention of pulmonary embolism formation
11/14/2013WO2013168172A1 Depot formulations of a local anesthetic and methods for preparation thereof
11/14/2013WO2013168167A1 Depot formulations of a hydrophobic active ingredient and methods for preparation thereof
11/14/2013WO2013167959A1 Myrrh based composition for otological use
11/14/2013WO2013167865A1 Pharmaceutical composition
11/14/2013WO2013167782A1 Amphiphilic copolymers carrying alpha-tocopherol having antitumoural properties
11/14/2013WO2013167742A1 Rapidly disintegrating monolayer film and use thereof in oral hygiene
11/14/2013WO2013167735A1 Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
11/14/2013WO2013167583A1 Pharmaceutical composition of a papillomavirus inhibitor
11/14/2013WO2013167233A1 Tobramycin formulation
11/14/2013WO2013167112A1 Composition for nasal application
11/14/2013WO2013166681A1 Composition for producing microcapsules and medicine made thereof
11/14/2013WO2013166604A1 Single-arm monovalent antibody constructs and uses thereof
11/14/2013WO2013166566A1 Biodegradable three-dimensional polymer material, and method for preparing a biodegradable three-dimensional polymer material
11/14/2013WO2013133543A9 Calcium carrier, and chelated calcium pha granule and microorganism comprising same
11/14/2013WO2013102842A4 Device and composition for drug release
11/14/2013WO2012136369A8 Ophthalmic preparations based on pacap (pituitary adenylate cyclase activating polypeptide) which restore the normal visual function in early glaucoma
11/14/2013US20130303799 Process for the preparation of poly(alkylene oxide) derivatives for modification of biologically active molecules and materials
11/14/2013US20130303627 Ophthalmic composition
11/14/2013US20130303626 Ophthalmic composition
11/14/2013US20130303623 Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
11/14/2013US20130303618 Solid Pharmaceutical Compositions Containing Pregabalin
11/14/2013US20130303615 Antimicrobial compositions and methods
11/14/2013US20130303587 Non-liposomal systems for nucleic acid delivery
11/14/2013US20130303556 Mucosal bioadhesive slow release carrier for delivering active principles
11/14/2013US20130303501 Pharmaceutical composition and method for treating hypogonadism
11/14/2013US20130303498 Inhalant Formulation Containing Sulfoalkyl Ether Cyclodextrin and Corticosteroid
11/14/2013US20130303494 Pharmaceutical Formulation Containing Gelling Agent
11/14/2013US20130303451 Long-acting polypeptides and methods of producing same
11/14/2013US20130303444 Crystalline forms of the di-sodium salt of n-(5-chlorosalicyloyl)-8-aminocaprylic acid
11/14/2013US20130303435 Smart Pro-Drugs of Serine Protease Inhibitors
11/14/2013US20130302425 Highly dispersible powders, compositions and methods for preparation
11/14/2013US20130302408 Carrier-Linked Magnetic Nanoparticle Drug Delivery Composition and Method of Use
11/14/2013US20130302405 Amino sugar-containing glucan, method for producing same, and use thereof
11/14/2013US20130302400 Combination therapy with an anti-hyaluronan agent and therapeutic agent
11/14/2013US20130302359 Cytotoxic benzodiazepine derivatives
11/14/2013US20130302357 Novel benzodiazepine derivatives
11/14/2013US20130302342 Human lactoferrin derived peptide for use as an antigen masking agent
11/14/2013US20130302324 Methods for treating retinopathy with extended therapeutic effect
11/14/2013US20130302317 Siglec-9 Binding Agents
11/14/2013US20130302309 Non-animal soft capsule shell composition having improved disintegration and shell hardness
11/14/2013US20130302281 Stable liquid interferon formulations
11/14/2013US20130302268 Active principle for mitigating undesired medical conditions
11/14/2013US20130302257 Compositions and Methods for Delivering Nucleic Acid Molecules and Treating Cancer
11/14/2013US20130302252 Polyarginine-coated magnetic nanovector and methods of use thereof
11/14/2013US20130302249 Intestinal peptide targeting ligands
11/14/2013US20130302246 Compositions and methods for delivering a substance to a biological target
11/14/2013DE102012009570A1 Komposition für nasale Anwendung Composition for nasal application
11/14/2013CA2873138A1 Compositions and methods for the treatment of local pain
11/14/2013CA2873087A1 Compositions and methods for the treatment of hyperglycemia
11/14/2013CA2873016A1 Compositions and methods for the treatment of epilepsy
11/14/2013CA2872976A1 Compositions and methods for the treatment of neurological disorders
11/13/2013EP2662096A1 Process for preparing maytansinoid antibody conjugates
11/13/2013EP2662095A1 Pyrrolobenzodiazepines and conjugates thereof
11/13/2013EP2662094A1 Cylodextrin Complexation Methods for Formulating Peptide Proteasome Inhibitors
11/13/2013EP2662093A1 Tobramycin formulation
1 ... 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 ... 1712